ArticleParasites & vectors2018
Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni.
Article in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Discovery and biological evaluation of novelMicrobiology spectrum · 2026Article
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- High-Throughput Screens of Repurposing Hub and DOS Chemical Libraries Reveal Compounds with Novel and Potent Inhibitory Activity Against the Essential Non-Neuronal Acetylcholinesterase ofInternational journal of molecular sciences · 2025Article
- Lessons learned from 20 years of preclinical testing in pediatric cancers.Pharmacology & therapeutics · 2024Review
- In Vitro Antischistosomal Activity ofJournal of tropical medicine · 2024Article
- Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022.ACS infectious diseases · 2023Review
- Schistosoma mansoni α-N-acetylgalactosaminidase (SmNAGAL) regulates coordinated parasite movement and egg production.PLoS pathogens · 2022Article
- Identification of hit compounds with anti-schistosomal activity on in vitro generated juvenile worms in cell-free medium.PLoS neglected tropical diseases · 2021Article
- Validation of a human-serum-based in vitro growth method for drug screening on juvenile development stages of Schistosoma mansoni.PLoS neglected tropical diseases · 2021Article
- Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?RSC medicinal chemistry · 2020Review
- Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery.Parasites & vectors · 2019Article
- Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Antimicrobial agents and chemotherapy · 2019Article
- Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni.Nature protocols · 2019Article
- Interactive online application for the prediction, ranking and prioritisation of drug targets in Schistosoma haematobium.Parasites & vectors · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe development of new treatments against schistosomiasis is imperative but lacks commercial interest. Drug repurposing represents a suitable strategy to identify potential treatments, which have already unblocked several essential steps along the drug development path, hence reducing costs and timelines. Promoting this approach, the Medicines for Malaria Venture (MMV) recently distributed a drug repurposing library of 400 advanced lead candidates (Stasis Box).
methodsAll 400 compounds were initially tested in vitro against the larval stage of Schistosoma mansoni at 10 μM. Hits progressed to screening on adult worms and were further characterised for IC
resultsEleven of the 37 compounds active on the larval stage were also highly active on adult worms in vitro (IC
conclusionsPhenotypic screening of advanced lead compounds is a simple and resource-low method to identify novel anthelminthics. None of the promising hits of the Stasis Box identified in vitro against S. mansoni yielded acceptable worm burden reductions in vivo, which might be due to the high plasma protein binding. Since the in vitro hits interfere with different drug targets, they might provide a starting point for target based screening and structure-activity relationship studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.